Abstract 2234P
Background
Immune checkpoint inhibitors (ICIs) can induce dramatic anti-tumor immune responses as well as significant immune-related adverse events (irAEs). While the drivers of irAEs are poorly understood, we hypothesized that inflammation against infiltrating tumor cells could result in local inflammation or a break in immune tolerance that drive a subset of irAEs in the infiltrated organ.
Methods
The medical records of cancer patients admitted to the Massachusetts General Hospital with concern for an irAE from Feb 2011 - Nov 2021 were reviewed for radiographic evidence of metastatic or primary tumors in the liver and/or lungs and a diagnosis of irHepatitis and/or irPneumonitis during admission. Cases with radiation to the irAE organ in the prior year were excluded. Multivariable analysis using logistic regression was used to obtain the odds ratios of irAEs in tumor-bearing organs. Pathology specimens of irAE tissues were reviewed for histologic evidence of tumor cells.
Results
384 hospitalized patients were identified (irHepatitis n=41, irPneumonitis n=30) (Table 2234P). Tumor-bearing liver was associated with irHepatitis (OR 2.4, 95% CI [1.2, 4.7], p = 0.011), even after considering only biopsy-proven cases of irHepatitis (n = 34, OR 2.6, 95% CI [1.2, 5.4], p = 0.0093). Tumor-bearing lungs were also associated with irPneumonitis (OR 2.6, 95% CI [1.1-6.6], p = 0.034). Both associations remained significant after adjusting for dual ICI use. Four cases from patients with irAEs further identified histological evidence of radiographically occult metastases in organs with irAEs. T-cell receptor sequencing of irAEs in tumor-bearing organs will be used to further define immunologic features of these irAEs. Table: 2234P
Patients with tumor-bearing organs and irAEs
Tumor-bearing liver | irHepatitis | ||
- | + | Total | |
- | 271 | 25 | 296 |
+ | 72 | 16 | 88 |
Total | 343 | 41 | 384 |
Tumor-bearing lung | irPneumonitis | ||
- | + | Total | |
- | 152 | 7 | 159 |
+ | 194 | 23 | 217 |
Total | 346 | 30 | 376* |
*8 cases were excluded due to recent lung irradiation |
Conclusions
In a pan-cancer cohort, radiographic evidence of tumor infiltration in the lung or liver is a risk factor for the development of irAEs in that same organ. Tumor infiltration may increase the risk for developing an irAEs in that organ, and these cases may have distinct molecular and clinical features.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S.M. Blum: Financial Interests, Personal, Stocks or ownership: 76 Bio, Kronos Bio, Allogene Therapeutics; Financial Interests, Personal, Speaker, Consultant, Advisor: Two River Consulting, Third Rock Ventures. L. Zubiri: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Merck. D.A. Zlotoff: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Freeline Therapeutics, Intrinsic Imaging. D. Juric: Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis, Genentech, Syros, Eisai, Vibliome, Mapkure, Relay Therapeutics, PIC Therapeutics; Financial Interests, Institutional, Research Funding: Novartis, Genentech, Syros, Eisai, Pfizer, Takeda, Ribon Therapeutics, Infinity, nventisBio 9RF, Cyteir, Blueprint, Arvinas. M. Dougan: Financial Interests, Personal, Speaker, Consultant, Advisor: ORIC Pharmaceuticals, Genentech, Sorriso Pharmaceuticals, Generate Biomedicines, Aditum, Palleon, Mallinckrodt Pharmaceuticals, Foghorn Therapeutics, Partner Therapeutics, SQZ Biotech, AzurRx, Moderna, Neoleukin Therapeutics, Veravas, Cerberus Therapeutics, Eli Lilly; Non-Financial Interests, Institutional, Research Grant: Eli Lilly. A. Villani: Financial Interests, Personal, Speaker, Consultant, Advisor: to Bristol Myers Squibb. K.L. Reynolds: Financial Interests, Personal, Advisory Board: SAGA Diagnostics; Financial Interests, Personal, Speaker, Consultant, Advisor: CME Outfitters, Medscape; Non-Financial Interests, Institutional, Research Funding: Bristol Myers Squibb. M. Mino-Kenudson: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Sanofi, Jansenn Oncology, Innate; Financial Interests, Personal, Royalties: Elsevier. R.J. Sullivan: Financial Interests, Personal, Advisory Board: Merck, Novartis, Bristol Myers Squibb, Eisai, Iovance, OncoSec, Pfizer, Replimune, Marengo; Financial Interests, Personal, Royalties: Up-To-Date; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Institutional, Local PI: GSK, Sanofi, Moderna, Biomed Valley Discoveries, Astex, Compugen, Beigene, Novartis, Rubius, Alkermes, Synthekine; Financial Interests, Institutional, Coordinating PI: Pfizer, Roche-Genentech, Simcha Therapeutics, OnKure, Marengo. All other authors have declared no conflicts of interest.
Resources from the same session
2150P - Clinical and molecular characterisation of cancer-associated venous thromboembolism (VTE)
Presenter: Pau Mascaró Baselga
Session: Poster session 07
2151P - Incidence patterns and clinical implications of venous thromboembolism (VTE) in patients (pts) with neuroendocrine tumors (NET)
Presenter: Jorge Hernando
Session: Poster session 07
2152P - Prognostic importance of GRIM score on sorafenib side effects, hospitalization and survival in hepatocellular cancer patients
Presenter: Duygu Ercan Uzundal
Session: Poster session 07
2153P - Circulating biomarkers to predict severe complications in cancer patients with low-risk chemotherapy-associated febrile neutropenia
Presenter: Sofía Wikström Fernandez
Session: Poster session 07
2154P - Total cholesterol as an independent prognostic factor in cancer patient survival: A single institution experience
Presenter: Maria Alameda-Guijarro
Session: Poster session 07
2156P - Use of taxanes during pregnancy: A systematic review
Presenter: Ana Ferrigno Guajardo
Session: Poster session 07
2157P - A phase II randomised controlled trial comparing the cardiotoxicity of capecitabine and S-1
Presenter: Sally Clive
Session: Poster session 07
2158P - A self-assessment survey to identify the risk of patient’s screen fail in phase I clinical trials (SCITEP trial)
Presenter: Kaissa Ouali
Session: Poster session 07
2159P - Machine learning algorithms to predict the risk of chemotherapy-related toxicity in older Asians
Presenter: Mingwei Li
Session: Poster session 07
2160P - Sociodemographic disparities associated with financial toxicity in stage IV non-small cell lung cancer survivors
Presenter: Mitchell Parma
Session: Poster session 07